Lilly to pay $22.5M in Zyprexa settlement; Glaxo nabs FDA approval for new vaccine;

> Eli Lilly will pay $22.5 million to settle a lawsuit brought by the state of West Virginia claiming the company improperly marketed its antipsychotic drug Zyprexa. Report

> GlaxoSmithKline got the FDA nod for its vaccine Hiberix, a booster shot that helps to prevent Haemophilus, a bacterial infection that can cause meningitis. Report

> The FDA announced that it had issued warning letters to eight companies marketing unlawful over-the-counter topical drug products containing the pain reliever ibuprofen. FDA release

> Bristol-Myers Squibb said it extended the deadline for its tender offer to buy shares of partner Medarex amid low shareholder support. Report

> Unichem got the FDA nod for its high blood pressure remedy bisprolol fumarate in two dosage strengths. Report

> Swiss drugs industry supplier Lonza outbid private equity group JLL for Canadian rival Patheon in a deal worth $460 million, seeking to boost its manufacturing capacity. Report

> GlaxoSmithKline wants to put up three wind turbines to generate up to 10 percent of the electricity used at its facility in Irvine, Scotland. Report

Biotech News

> Massachusetts economic development officials are likely whooping it up this morning on the news that the UK's Shire is significantly upping the ante for the planned expansion of its Human Genetic Therapies unit in Lexington, MA. Report

> With a next-gen platinum chemotherapy in late-stage tests, South San Francisco-based Poniard Pharmaceuticals struck a deal to sell up to $60 million in company stock to an investor. Report

> A new form of online matchmaking could offer drug developers added hope for achieving one of their greatest desires: More efficient clinical trial recruitment. Pfizer is teaming up with the IT outfit Private Access to create a social networking site that can help bring together patients and clinical trial researchers. Report

> After treating investors to a wild ride this year--with shares first shooting up and then falling back to earth on its hep C data--Anadys is telling Xconomy that it's poised to ride along at a more soothing pace in the months to come. Report

> s of Anika Therapeutics soared as much as 62 percent this morning after the Bedford, MA-based developer announced that its osteoarthritis therapy won marketing approval in Canada. Report

And Finally... Think you can do a better job handling a flu pandemic? Check out The Great Flu, the first online pandemic flu game. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.